Elbit Imaging Ltd (EMITF)

[midastouch017]

Elbit Imaging Ltd. Announces that First Treatment was Performed Under Insightech's Phase I Clinical Trial for Opening the Blood Brain Barrier in Patients with Early Alzheimer's Disease

TEL AVIV, ISRAEL / ACCESSWIRE / March 27, 2017 / Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that the first treatment was performed under Phase I clinical trial to investigate the use of Magnetic Resonance Imaging guided by Focused Ultrasound (MRgFUS) technology for opening the blood brain barrier in patients with early Alzheimer's disease. The treatment was conducted at Sunnybrook Health Sciences Centre in Toronto, Canada and use the INSIGHTEC's Exablate Neuro system. INSIGHTEC is the regulatory sponsor of the clinical trial.

The purpose of the study is to evaluate the safety and feasibility of low frequency MRgFUS to temporarily open the blood-brain barrier ("BBB") in patients with mild to moderate Alzheimer's disease. This is the first human application of MRgFUS in Alzheimer's patients.

The BBB is a protective barrier that restricts the passage of substances from the bloodstream into the brain, protecting it from toxic chemicals. This barrier also prevents the delivery of essential medication to reach the brain.

The Company holds approximately 89.9% of the share capital of Elbit Medical Technologies Ltd. (TASE:EMTC-M) (85.8% on a fully diluted basis) which, in turn, holds approximately 31.3% of the share capital in INSIGHTEC (26.6% on a fully diluted basis).